Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A

P and T Approvals, Tramadol Change, Warnings About Promacta and Sporanox

Pharmacy Focus

See highlights of the June 3 meeting of the Pharmacy and Therapeutics Committee. Also, tramadol is now being managed as a controlled substance, and the federal government has released a warning about Promacta and a list of contraindications for Sporanox.

» Read more

Meetings and Events

Grand Rounds

Click here to view upcoming grand rounds.

Upcoming CME Conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - August 2014 (PDF)


Do you know of a significant event in the life of a medical staff member? Please let us know, and we'll post these milestones in Medical Staff Pulse. Also, feel free to submit comments on milestones, and we'll post the comments in the next issue. Click here to email us your milestones and comments.

» Read more

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

Risk Is Low, but Know Ebola Recommendations

By Rekha Murthy, MD, Medical Director, Department of Hospital Epidemiology

There is currently a large outbreak of Ebola virus disease (EVD) in the West African countries of Guinea, Sierra Leone and Liberia. Although the risk of an Ebola outbreak in the U.S. is extremely low, healthcare providers should be aware of the clinical presentation of Ebola illness in individuals who have returned within 21 days from areas where outbreaks of Ebola have been confirmed.

Early recognition is critical for infection control. Notify Hospital Epidemiology immediately at 310-423-5574 of any suspected cases of EVD.

EVD should be considered in the case of illness in a person who has both consistent symptoms and risk factors as follows:

  • Clinical criteria that include:
    • Fever of greater than 38.6 degrees Celsius (101.5 degrees Fahrenheit)
    • And additional symptoms such as severe headache, muscle pain, vomiting, diarrhea, abdominal pain or unexplained hemorrhage
  • And epidemiologic risk factors within the three weeks before the onset of symptoms, such as:
    • Contact with blood or other body fluids of a patient known or suspected to have EVD
    • Residence in or travel to an area where EVD transmission is active
    • Direct handling of bats, rodents or primates from disease-endemic areas

Isolation and Testing

Pre-emptive standard, contact and droplet precautions are recommended for management of hospitalized patients with known or suspected EVD.

Testing for EVD must be coordinated with Hospital Epidemiology and the Cedars-Sinai lab through local public health agencies.

Malaria diagnostics should be a part of initial testing, as malaria is a common cause of febrile illness in persons who have traveled to the affected countries.

Additional information, including updates, frequently asked questions and current advisories, is available on the website of the U.S. Centers for Disease Control and Prevention and on the Hospital Epidemiology Intranet site.